# South Korean pharmaceutical and biotech industry development

> Developing situation record from CLSTR: https://clstr.news/situations/south-korean-pharmaceutical-and-biotech-industry-development
> Updated: 2026-11-12T00:50:03.000Z. Sources: 6. Developments: 3.

The South Korean government, through the Ministry of Health and Welfare and the Ministry of SMEs and Startups, announced a strategic plan to foster 200 “K-pharmaceutical and bio frontier companies” by 2030. This initiative provides support for small and medium-sized enterprises across various stages, including drug candidate discovery, clinical trials, and global expansion. The plan includes annual selections in sectors such as new drug development, medical devices, and biomaterials, supported by specialized R&D banks providing significant investment and commercialization guarantees.

In line with these growth objectives, South Korean firms have intensified their pursuit of international partnerships. At the BIO-Europe 2026 conference in Cologne, Germany, approximately 210 South Korean companies participated, making South Korea the fourth largest national delegation at the event. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) engaged with international organizations, such as the U.S. Biotechnology Innovation Organization (BIO), to discuss regulatory cooperation and business matching.

Specific companies highlighted their assets during these forums. Alteogen promoted its Hybrozyme subcutaneous injection platform and its multi-target macular degeneration drug candidate, ALTS-OP01, aiming to transition from a platform provider to a drug licensor. Jeil Pharmaceutical sought collaborations for its dual SGLT1/SGLT2 inhibitor, JP-2266, its SOS1 inhibitor, JP9441, and its diabetes combination therapy, Duglow. Domestically, at BioPlus-Interphex Korea 2026, the Hwasun Chonnam National University Hospital Advanced Precision Medical Industry Support Center facilitated over 100 consultations for regional firms, including NPK Bio, Kablu Bio, and VS Pharmtech, regarding manufacturing and investment.

## Timeline

### 2026-11-12: South Korean biotech industry seeks global expansion at international forums

South Korean biotech firms and industry associations are leveraging major events like BioEurope 2026 and BioPlus-Interphex to secure global partnerships, investment, and manufacturing collaborations.

3 sources. https://clstr.news/cluster/south-korean-biotech-industry-seeks-global-expansion-at-international-forums

### 2026-11-08: South Korean biotech firms target global partnerships at BIO-Europe 2026

South Korean companies Alteogen and Jeil Pharmaceutical are attending BIO-Europe 2026 in Germany to secure global licensing deals for new drug candidates in oncology, diabetes, and ophthalmology.

5 sources. https://clstr.news/cluster/south-korean-biotech-firms-target-global-partnerships-at-bio-europe-2026

### 2026-10-29: South Korea to foster 200 K-pharmaceutical and bio frontier companies by 2030

South Korea will select 50 promising pharmaceutical and bio companies annually to nurture 200 frontier firms by 2030, providing R&D, clinical, and financial support.

3 sources. https://clstr.news/cluster/south-korea-to-foster-200-k-pharmaceutical-and-bio-frontier-companies-by-2030

---
Cite as: South Korean pharmaceutical and biotech industry development. CLSTR, https://clstr.news/situations/south-korean-pharmaceutical-and-biotech-industry-development
